I-O Optimise rationale and methodology publications
S Ekman, F Griesinger, P Baas, D Chao, C Chouaid, JC O'Donnell, JR Penrod, M Daumont, L Lacoin, A McKenney, M Khovratovich, RE Munro, I Durand-Zaleski, SP Johnsen.
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15:1551–1563.
/10.2217/fon-2019-0025
I-O Optimise data publications
M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Gonçalves.
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulm Med. 2020;20:240.
track/pdf/10.1186/s12890-020-01270-z.pdf
M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Gonçalves.
Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database. Lung Cancer Manag. 2021;10:LMT46.
articles/PMC8162184/pdf/lmt-10-46.pdf
S Ekman, P Horvat, M Rosenlund, AM Kejs, D Patel, A Juarez-Garcia, L Lacoin, MJ Daumont, JR Penrod, OT Brustugun, JB Sørensen.
Epidemiology and survival outcomes for patients with NSCLC in Scandinavia in the preimmunotherapy era: a SCAN-LEAF retrospective analysis from the I-O Optimise initiative.
JTO Clin Res Rep. 2021;2:100165.
M Snee, S Cheeseman, M Thompson, M Riaz, W Sopwith, L Lacoin, C Chaib, MJ Daumont, JR Penrod, JC O'Donnell, G Hall.
Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O Optimise initiative.
BMJ Open. 2021;11:e043442.
bmjopen/11/5/e043442.full.pdf
M Snee, S Cheeseman, M Thompson, M Riaz, W Sopwith, L Lacoin, C Chaib, MJ Daumont, JR Penrod, G Hall.
Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative. BMJ Open. 2021;11:e046396.
11/9/e046396.long
P Baas, MJ Daumont, L Lacoin, JR Penrod, R Carroll, S Venkatesh, A Ubhi, M Snee.
Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: a nationwide CAS registry analysis from the I-O Optimise initiative.
Lung Cancer. 2021;162:185–193.
S0923-7534(20)41448-6/fulltext
JB Sorensen, P Horvat, M Rosenlund, AM Kejs, D Patel, A Juarez-Garcia, L Lacoin, MJ Daumont, JR Penrod, JC O'Donnell, OT Brustugun, S Ekman.
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
Future Oncol. 2022;18:205–214.
10.2217/fon-2021-0746?rfr_dat=
cr_pub++0pubmed&url_ver=Z39.88-200
3&rfr_id=ori%3Arid%3Acrossref.org
R Carroll, M Bortolini, A Calleja, R Munro, S Kong, MJ Daumont, JR Penrod, K Lakhdari, L Lacoin, WY Cheung.
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
BMC Cancer. 2022 Mar 10;22(1):255.
articles/10.1186/s12885-022-09342-5
F Griesinger, M Pérol, N Girard, I Durand-Zaleski, S Zacharias, L Bosquet, M Jänicke, X Quantin, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, MJ Daumont, JR Penrod, R Carroll, D Waldenberger, D Reynaud, M Thomas, C Chouaid.
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Lung Cancer. 2022 Oct;172:65-74.
S0169-5002(22)00577-3/fulltext
C Chouaid, M Thomas, D Debieuvre, I Durand-Zaleski, S Zacharias, L Bosquet, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, MJ Daumont, JR Penrod, R Carroll, D Waldenberger, F-E Cotté, C Audigier-Valette, F Griesinger.
Effectiveness of nivolumab in second-Line and later in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: analysis of the ESME-AMLC and CRISP cohorts.
Cancers. 2022;14(24): 6148.
A Wolf, JA Stratmann, S Shaid, N Niklas, A Calleja, H Ubhi, R Munro, D Waldenberger, R Carroll, MJ Daumont, JR Penrod, L Lacoin, G Rohde.
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
BMC Pulm Med. 2023 Jan 13;23(1):16.
articles/10.1186/s12890-022-02288-1
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol‑Myers Squibb Company.
Home Corporate Website Contact
Sitemap Privacy Policy
Legal Notice
